SciHonic Life Sciences Completes Tens of Millions RMB Pre-A Financing to Advance Innovative Energy-Based Medical Devices

Recently, ScieHome announced the completion of its tens-of-millions RMB Pre-A financing round. This round was led by Oriza Holdings, with follow-on investment from existing shareholder Ruihong Investment. Xingyuan Zhitong served as the exclusive financial advisor for this transaction.

Shanghai ScieHome Life Sciences Co., Ltd. was established in June 2022 and is a technology-driven medical enterprise dedicated to building platforms based on ultrasound energy technology and combined drug-device technologies.

Focusing on interventional ultrasound technology and drug-device combination technology, ScieHome has established a series of technical platforms, including interventional ultrasound energy technology, drug-device combination technology, software and algorithm architecture technology, and an industrial translation platform. The company is continuously developing innovative energy-based medical devices that truly address clinical pain points. Its first core product, the SciHonic Ultrasound-Assisted Thrombectomy System, leverages multidisciplinary foundational technological expertise to deliver a solution more closely aligned with real-world clinical scenarios. The product has currently entered the registration-related clinical trial phase.

The founding team of ScieHome possesses rare R&D and industrialization expertise in China. The company’s founder previously served as the project lead for Firehawk, MicroPort’s star coronary targeted drug-eluting stent system, bringing nearly 20 years of experience in industrial R&D and management. The core founding team combines extensive industry and entrepreneurial experience in ultrasonic energy R&D, pharmaceutical-device synergy, regulatory and quality management, product commercialization, and startup operations. Team members have held senior executive positions at renowned domestic and international enterprises such as MicroPort and Philips Healthcare for over a decade, making ScieHome’s founding team highly innovative and adept at industrialization.

Mr. Wu Changsheng, Founder of ScieHomestated, “We are deeply honored to partner with Oriza Holdings, a renowned venture capital firm in the industry. We sincerely appreciate the recognition and support from both new and existing shareholders for ScieHome, and extend special thanks to our highly efficient ScieHome team. Addressing clinical pain points and meeting the demands of real-world application scenarios to benefit patients and physicians alike remains our steadfast commitment to continuous innovation. The completion of this financing round will enable the company to accelerate the clinical development and partial commercialization of its core products. We eagerly anticipate bringing our products to market soon to address the substantial unmet therapeutic needs in clinical practice.”

Mr. Zhao Qun, Partner at Oriza Holdings“Vascular disease represents a critical clinical domain, where countless patients continue to face life-threatening risks or severe health complications. Leveraging robust technical reserves and strong execution capabilities, the ScieHome team has advanced its flagship ultrasound-based thrombectomy product—a leading innovation in its class—to the clinical stage within a short timeframe and under resource constraints. Oriza Holdings remains bullish on the vascular disease market and is continuously refining its strategic layout. We are honored to partner with the ScieHome team through this investment and look forward to seeing these innovative products benefit a broad patient population at the earliest opportunity.”

Mr. Zhu Dahang, Partner at Ruihong Investmentstated: “It is a great honor to become a partner of ScieHome. There are numerous unmet clinical needs, with interventional energy technology representing a significant therapeutic direction. The ScieHome team has accumulated years of technical expertise in implantable devices and the ultrasound industry, having successfully developed multiple products in the past. We are confident that it will continue to deliver clinically competitive therapeutic products with international competitiveness.”

Mr. Shen Yuxiao, Managing Director of Xingyuan Zhitongstated: “The ScieHome team possesses extensive expertise in product development and industrialization. The rapid advancement of its core products also demonstrates the company’s strong execution capabilities. We are highly optimistic about the future industry competitiveness and commercial potential of the company’s products. Once again, congratulations to the company, as well as to both new and existing investors.”

Oriza YuanDian is a specialized early-stage equity investment platform under Oriza Holdings, operating on market-oriented principles. It focuses primarily on investment opportunities in startups and early-growth enterprises within the technology and healthcare sectors. With a total fund size exceeding RMB 7 billion, it manages both venture capital (VC) funds and angel funds targeted at specific regions.

Since its establishment in 2013, Oriza Holdings has maintained an investment style focused on early-stage ventures, with a preference for technology-driven companies and a steadfast commitment to its promises, earning a strong reputation among early-stage tech startups. To date, it has invested in over 280 companies, dedicated to empowering their growth and evolving alongside entrepreneurs.

Ruihong Investment Team boasts nearly two decades of experience in equity investment. Leveraging both proprietary and entrusted capital, the team has established a comprehensive investment strategy spanning project incubation, early-stage venture capital, and mid-to-late-stage equity investments. Dedicated to identifying and empowering outstanding founders and teams, Ruihong has cumulatively invested tens of billions of yuan, with multiple portfolio companies successfully achieving public listings.

StartPointAdvisors is committed to building a top-tier next-generation healthcare investment bank in China. Established in 2020, the firm is headquartered in Beijing and Shanghai, with a team comprising professionals from renowned industry institutions who possess extensive practical experience. Over the past four years, StartPointAdvisors has covered all mainstream sub-sectors and financing stages within the industry. It is also one of the few firms in China with proven transaction success across private equity financing, mergers and acquisitions (M&A), business development (BD), and exit strategies via share transfers.